Cargando…
Oleogel-S10 Phase 3 study “EASE” for epidermolysis bullosa: study design and rationale
BACKGROUND: Epidermolysis bullosa (EB) is a group of rare, genetic diseases that affect the integrity of epithelial tissues, most notably the skin. Patients experience recurrent skin wounding, with severity depending on type, sub-type, and mutation. Oleogel-S10, a formulation of birch bark extract,...
Autores principales: | Kern, Johannes S., Schwieger-Briel, Agnes, Löwe, Sandra, Sumeray, Mark, Davis, Charles, Martinez, Anna E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6560757/ https://www.ncbi.nlm.nih.gov/pubmed/31186047 http://dx.doi.org/10.1186/s13063-019-3362-z |
Ejemplares similares
-
Mechanism of Oleogel‐S10: A triterpene preparation for the treatment of epidermolysis bullosa
por: Schwieger‐Briel, Agnes, et al.
Publicado: (2019) -
Betulin-Based Oleogel to Improve Wound Healing in Dystrophic Epidermolysis Bullosa: A Prospective Controlled Proof-of-Concept Study
por: Schwieger-Briel, Agnes, et al.
Publicado: (2017) -
Consensus guidelines for diagnosis and management of anemia in epidermolysis bullosa
por: Liy-Wong, Carmen, et al.
Publicado: (2023) -
EGFR inhibition for metastasized cutaneous squamous cell carcinoma in dystrophic epidermolysis bullosa
por: Diociaiuti, Andrea, et al.
Publicado: (2019) -
A comparison study of outcome measures for epidermolysis bullosa: Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) and the Instrument for Scoring Clinical Outcomes of Research for Epidermolysis Bullosa (iscorEB)
por: Rogers, Clare L., et al.
Publicado: (2021)